MY150237A - Cripto blocking antibodies and uses thereof - Google Patents

Cripto blocking antibodies and uses thereof

Info

Publication number
MY150237A
MY150237A MYPI2010003173A MYPI20103173A MY150237A MY 150237 A MY150237 A MY 150237A MY PI2010003173 A MYPI2010003173 A MY PI2010003173A MY PI20103173 A MYPI20103173 A MY PI20103173A MY 150237 A MY150237 A MY 150237A
Authority
MY
Malaysia
Prior art keywords
cripto
antibodies
bind
modulate
tumor growth
Prior art date
Application number
MYPI2010003173A
Other languages
English (en)
Inventor
Michele Sanicola-Nadel
Kevin Williams
Susan Schiffer
Paul Rayhorn
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27501437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY150237(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of MY150237A publication Critical patent/MY150237A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI2010003173A 2001-04-26 2002-04-23 Cripto blocking antibodies and uses thereof MY150237A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28678201P 2001-04-26 2001-04-26
US29302001P 2001-05-17 2001-05-17
US30109101P 2001-06-26 2001-06-26
US36700202P 2002-03-22 2002-03-22

Publications (1)

Publication Number Publication Date
MY150237A true MY150237A (en) 2013-12-31

Family

ID=27501437

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI20021484A MY157382A (en) 2001-04-26 2002-04-23 Cripto blocking antibodies and uses thereof.
MYPI2010003173A MY150237A (en) 2001-04-26 2002-04-23 Cripto blocking antibodies and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MYPI20021484A MY157382A (en) 2001-04-26 2002-04-23 Cripto blocking antibodies and uses thereof.

Country Status (33)

Country Link
US (6) US7531174B2 (OSRAM)
EP (3) EP2316486A3 (OSRAM)
JP (4) JP4307845B2 (OSRAM)
KR (1) KR100592357B1 (OSRAM)
CN (1) CN100352501C (OSRAM)
AR (3) AR037223A1 (OSRAM)
AT (2) ATE533508T1 (OSRAM)
BG (1) BG108363A (OSRAM)
BR (1) BR0209254A (OSRAM)
CA (2) CA2715570A1 (OSRAM)
CL (1) CL2009002199A1 (OSRAM)
CY (1) CY1108960T1 (OSRAM)
CZ (1) CZ20033208A3 (OSRAM)
DE (1) DE60230868D1 (OSRAM)
DK (1) DK1390389T3 (OSRAM)
EA (1) EA007469B1 (OSRAM)
EE (1) EE200300528A (OSRAM)
ES (1) ES2321065T3 (OSRAM)
GE (1) GEP20074091B (OSRAM)
HU (1) HUP0501113A3 (OSRAM)
IS (1) IS2662B (OSRAM)
MX (1) MXPA03009797A (OSRAM)
MY (2) MY157382A (OSRAM)
NO (1) NO20034805L (OSRAM)
NZ (1) NZ566268A (OSRAM)
PL (1) PL207087B1 (OSRAM)
PT (1) PT1390389E (OSRAM)
RS (2) RS20110024A (OSRAM)
SG (1) SG157951A1 (OSRAM)
SI (1) SI1390389T1 (OSRAM)
SK (1) SK14432003A3 (OSRAM)
TR (1) TR200301846T2 (OSRAM)
WO (1) WO2002088170A2 (OSRAM)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090123470A1 (en) * 2001-03-26 2009-05-14 The Macfarlane Burnet Istitute For Medical Research And Public Health Ltd. Antibodies Against Cancer
AUPR395801A0 (en) 2001-03-26 2001-04-26 Austin Research Institute, The Antibodies against cancer
US7582299B2 (en) 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
JP4307845B2 (ja) 2001-04-26 2009-08-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｃｒｉｐｔｏをブロックする抗体およびその使用
EP1494693B1 (en) * 2002-03-22 2010-12-08 Biogen Idec MA Inc. Cripto-specific antibodies
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
US20050163782A1 (en) 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
WO2005028433A2 (en) * 2003-09-15 2005-03-31 Research Development Foundation CRIPTO ANTAGONISM OF ACTIVIN AND TGF-β SIGNALING
SG149815A1 (en) 2003-11-06 2009-02-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
WO2006074397A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Cripto binding molecules
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
EP2074209A2 (en) * 2006-07-28 2009-07-01 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
WO2008150530A2 (en) * 2007-06-01 2008-12-11 Biogen Idec Ma Inc. Cripto binding molecules
EP2279414A4 (en) * 2008-04-21 2011-06-29 Merck Sharp & Dohme PANCREATIC BETA CELL MASSE BIOMARKERS
CA2743057C (en) * 2008-11-07 2019-11-26 Research Development Foundation Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling
EP2475391B1 (en) 2009-09-09 2018-09-12 Centrose, LLC Extracellular targeted drug conjugates
TWI540136B (zh) 2010-04-15 2016-07-01 梅迪繆思有限公司 吡咯并苯并二氮呯及其共軛物
AU2011265054B2 (en) 2010-06-08 2016-09-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
CA2816426A1 (en) 2010-11-17 2012-06-07 Genentech, Inc. Alaninyl maytansinol antibody conjugates
AU2012228100B2 (en) 2011-03-17 2016-09-08 The University Of Birmingham Re-directed immunotherapy
RU2610336C2 (ru) 2011-04-21 2017-02-09 Сиэтл Дженетикс, Инк. Новые конъюгаты связывающее соединение - активное соединение (adc) и их применение
EP2707723B1 (en) 2011-05-12 2016-02-10 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
SG11201401406YA (en) 2011-10-14 2014-05-29 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
NZ707534A (en) 2012-10-12 2018-08-31 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
EP2906253B9 (en) 2012-10-12 2019-02-27 ADC Therapeutics SA Pyrrolobenzodiazepine - anti-psma antibody conjugates
RS57104B1 (sr) 2012-10-12 2018-06-29 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-antitela
WO2014057120A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
AU2013328580B2 (en) 2012-10-12 2016-01-21 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
JP6392765B2 (ja) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ ピロロベンゾジアゼピン−抗体結合体
EA032986B1 (ru) 2012-12-21 2019-08-30 Медимьюн Лимитед Пирролобензодиазепины
CA2894961C (en) 2012-12-21 2020-09-15 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
MX362970B (es) 2013-03-13 2019-02-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
US9649390B2 (en) 2013-03-13 2017-05-16 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
TWI680766B (zh) 2013-03-13 2020-01-01 英商梅迪繆思有限公司 吡咯并苯并二氮呯及其共軛物
EP3033111B1 (en) 2013-08-12 2019-03-13 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015095227A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
BR112016013258A2 (pt) 2013-12-16 2018-01-16 Genentech Inc composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit
CN105873614B (zh) 2013-12-16 2020-10-30 基因泰克公司 肽模拟化合物及其抗体-药物缀合物
PE20160996A1 (es) 2013-12-23 2016-11-09 Bayer Pharma AG Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
BR112017003236A2 (pt) 2014-09-12 2017-11-28 Genentech Inc anticorpos elaborados com cisteína, conjugados de droga e anticorpos, método de preparação de conjugado de droga e anticorpo e composição farmacêutica
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN107073136A (zh) 2014-09-17 2017-08-18 健泰科生物技术公司 吡咯并苯并二氮杂卓及其抗体二硫化物偶联物
BR112017011111A2 (pt) 2014-11-25 2017-12-26 Adc Therapeutics Sa conjugados de pirrolobenzodiazepina-anticorpo
WO2016090050A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
US20180125936A1 (en) * 2015-04-07 2018-05-10 Paranta Biosciences Limited Method of treating neoplasias
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
PE20180610A1 (es) 2015-06-22 2018-04-09 Bayer Pharma AG CONJUGADOS DE LIGADOR-PRINCIPIO ACTIVO (ADCs) Y CONJUGADOS DE LIGADOR-PROFARMACO (APDCs) CON GRUPOS ENZIMATICAMENTE ESCINDIBLES
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017162663A1 (de) 2016-03-24 2017-09-28 Bayer Pharma Aktiengesellschaft Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
EP3465221B1 (en) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
EP3919518A1 (en) 2016-06-15 2021-12-08 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
CN109689111B (zh) 2016-08-11 2024-04-05 基因泰克公司 吡咯并苯并二氮杂䓬前药及其抗体缀合物
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
BR112019011277A2 (pt) 2016-12-02 2019-10-22 University Of Southern California polinucleotídeo, sistema de expressão recombinante, vetor, polipeptídeo, célula recombinante, polipeptídeo de receptor imune sintético isolado ou heterodímero de polipeptídeo, célula efetora imune ou célula-tronco, população de células imunes ou efetoras, métodos de fabricação de uma célula efetora imune que expressa sir, de geração de uma população de células modificadas por rna, de fornecimento de imunidade antidoença e de tratamento ou prevenção de uma doença, composição, uso ou método, kit, e, sequência de aminoácidos.
US11433140B2 (en) 2016-12-21 2022-09-06 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (ADCs) having KSP inhibitors
CN110312533B (zh) 2016-12-21 2023-11-03 拜耳公司 具有酶促可裂解的基团的细胞毒性活性剂的前药
IL310558B1 (en) 2016-12-21 2025-10-01 Bayer Pharma AG Antibody-drug conjugates with enzymatically cleavable groups
BR112019016373B1 (pt) 2017-02-08 2022-01-25 Medimmune Limited Conjugado anticorpo-fármaco que se liga ao axl, composição e composição farmacêutica que compreende o mesmo e uso terapêutico do dito conjugado
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
US11370801B2 (en) 2017-04-18 2022-06-28 Medimmune Limited Pyrrolobenzodiazepine conjugates
EP3612234B1 (en) 2017-04-20 2024-03-13 ADC Therapeutics SA Combination therapy with an anti-axl antibody-drug conjugate
JP7145891B2 (ja) 2017-06-14 2022-10-03 アーデーセー セラピューティクス ソシエテ アノニム 抗ｃｄ１９ ａｄｃを投与するための投与レジメ
PT3668874T (pt) 2017-08-18 2022-02-24 Medimmune Ltd Conjugados de pirrolobenzodiazepina
EP3684773A1 (en) 2017-09-20 2020-07-29 pH Pharma Co., Ltd. Thailanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
IL316090A (en) 2018-06-01 2024-12-01 Eisai R&D Man Co Ltd Antibody-drug conjugates of splicing modulators and methods of use
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
WO2020086858A1 (en) 2018-10-24 2020-04-30 Genentech, Inc. Conjugated chemical inducers of degradation and methods of use
CN113227119A (zh) 2018-12-10 2021-08-06 基因泰克公司 用于与含Fc的蛋白质进行位点特异性缀合的光交联肽
PH12021551389A1 (en) 2018-12-13 2022-05-16 Eisai R&D Man Co Ltd Herboxidiene antibody-drug conjugates and methods of use
WO2020131697A2 (en) 2018-12-17 2020-06-25 Revitope Limited Twin immune cell engager
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
MX2021010477A (es) 2019-03-15 2021-10-01 Medimmune Ltd Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
CN120417934A (zh) 2022-12-23 2025-08-01 基因泰克公司 Cereblon降解剂缀合物及其用途
AU2024257248A1 (en) 2023-04-17 2025-11-06 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
TW202532437A (zh) * 2023-12-19 2025-08-16 德商拜恩技術股份公司 Cfc1結合分子
WO2025132976A1 (en) * 2023-12-19 2025-06-26 BioNTech SE Cfc1 binding molecule

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) * 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5780029A (en) 1989-11-14 1998-07-14 New York Medical College Antidiotypic monoclonal antibodies for treatment of melanoma
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5264557A (en) 1991-08-23 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Polypeptide of a human cripto-related gene, CR-3
US6063379A (en) 1993-12-09 2000-05-16 Centro De Inmunologia Molecular Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies
US5981215A (en) * 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
ES2312177T3 (es) * 1996-05-22 2009-02-16 Viventia Biotech Inc. Fragmentos de union a antigenos que detectan especificamente celulas cancerosas, nucleotidos que codifican los fragmentos y el uso de los mismos para la profilaxis y deteccion de canceres.
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
CA2356215C (en) 1998-12-23 2015-11-24 Pfizer Inc. Human monoclonal antibodies to ctla-4
WO2000052204A2 (en) 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
WO2000058499A1 (fr) 1999-03-30 2000-10-05 Japan Tobacco Inc. Procede pour la production d'anticorps monoclonal
EP1179178A1 (en) * 1999-04-20 2002-02-13 William J. Kokolus Improved method of identifying and locating immunobiologically-active linear peptides
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
JP2001046066A (ja) 1999-08-03 2001-02-20 Kyowa Hakko Kogyo Co Ltd 新規な相補性決定領域を有するヒトｖｅｇｆ受容体ｋｄｒに対する抗体
AU778199B2 (en) 1999-10-29 2004-11-25 Genentech Inc. Anti-prostate stem cell antigen (PSCA) antibody compositions and methods of use
US6663613B1 (en) 2000-01-25 2003-12-16 Bacchus Vascular, Inc. System and methods for clot dissolution
JP3926153B2 (ja) 2000-03-03 2007-06-06 協和醗酵工業株式会社 遺伝子組換え抗体およびその抗体断片
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
GB0020953D0 (en) 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
NZ525380A (en) 2000-09-18 2008-06-30 Biogen Idec Inc Non-fucosylated forms of Cripto and their use as tumor blocking agents
CA2434694C (en) 2001-01-26 2012-09-18 Caterina Bianco Detection and quantification of cripto-1
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
NZ545176A (en) 2001-01-29 2008-05-30 Biogen Idec Inc Modified antibodies reactive with CD20 and methods of use
AUPR395801A0 (en) * 2001-03-26 2001-04-26 Austin Research Institute, The Antibodies against cancer
US7582299B2 (en) * 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
JP4307845B2 (ja) * 2001-04-26 2009-08-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｃｒｉｐｔｏをブロックする抗体およびその使用
EP2153843B1 (en) * 2001-09-18 2012-08-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20040014690A1 (en) 2002-02-13 2004-01-22 Zhenkun Ma Macrolides with activity against methicillin-resistant staphylococcus aureus
EP1494693B1 (en) * 2002-03-22 2010-12-08 Biogen Idec MA Inc. Cripto-specific antibodies
WO2005028433A2 (en) * 2003-09-15 2005-03-31 Research Development Foundation CRIPTO ANTAGONISM OF ACTIVIN AND TGF-β SIGNALING
WO2006074397A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Cripto binding molecules
WO2007127461A2 (en) * 2006-04-28 2007-11-08 Biogen Idec Ma Inc. Composition and methods for the detection of cripto-3

Also Published As

Publication number Publication date
EA200301158A1 (ru) 2005-06-30
BG108363A (bg) 2004-09-30
RS20110024A (sr) 2011-08-31
DE60230868D1 (de) 2009-03-05
DK1390389T3 (da) 2009-04-20
US20090285818A1 (en) 2009-11-19
US20040146940A1 (en) 2004-07-29
ATE533508T1 (de) 2011-12-15
MXPA03009797A (es) 2004-01-29
TR200301846T2 (tr) 2006-10-26
EA007469B1 (ru) 2006-10-27
PL373513A1 (en) 2005-09-05
SG157951A1 (en) 2010-01-29
CL2009002199A1 (es) 2010-05-07
KR20040028744A (ko) 2004-04-03
JP2005314436A (ja) 2005-11-10
PT1390389E (pt) 2009-04-03
EP1390389A4 (en) 2004-09-22
CY1108960T1 (el) 2014-07-02
EP1390389A2 (en) 2004-02-25
ES2321065T3 (es) 2009-06-02
BR0209254A (pt) 2006-10-03
MY157382A (en) 2016-06-15
EP1390389B1 (en) 2009-01-14
AR072554A2 (es) 2010-09-08
CN1606453A (zh) 2005-04-13
PL207087B1 (pl) 2010-10-29
SI1390389T1 (sl) 2009-06-30
JP2004534020A (ja) 2004-11-11
IS2662B (is) 2010-08-15
US20080166341A1 (en) 2008-07-10
CZ20033208A3 (en) 2004-03-17
SK14432003A3 (sk) 2004-07-07
HUP0501113A2 (en) 2007-05-02
GEP20074091B (en) 2007-04-25
CA2715570A1 (en) 2002-11-07
IS6999A (is) 2003-10-24
US20100202962A1 (en) 2010-08-12
NO20034805D0 (no) 2003-10-27
YU84903A (sh) 2006-05-25
WO2002088170A2 (en) 2002-11-07
CN100352501C (zh) 2007-12-05
US20090286265A1 (en) 2009-11-19
RS51635B (sr) 2011-08-31
CA2443840A1 (en) 2002-11-07
EP1974749B1 (en) 2011-11-16
ATE420659T1 (de) 2009-01-15
NZ566268A (en) 2009-09-25
JP2010163438A (ja) 2010-07-29
JP2009108100A (ja) 2009-05-21
AR077759A2 (es) 2011-09-21
US8003763B2 (en) 2011-08-23
EE200300528A (et) 2004-08-16
KR100592357B1 (ko) 2006-06-22
WO2002088170A3 (en) 2003-12-24
US20120195912A1 (en) 2012-08-02
CA2443840C (en) 2010-10-26
HK1058935A1 (en) 2004-06-11
HUP0501113A3 (en) 2007-12-28
EP1974749A1 (en) 2008-10-01
EP2316486A3 (en) 2011-09-07
EP2316486A2 (en) 2011-05-04
US7531174B2 (en) 2009-05-12
US8673303B2 (en) 2014-03-18
NO20034805L (no) 2003-12-23
JP4307845B2 (ja) 2009-08-05
US7674462B2 (en) 2010-03-09
JP4575983B2 (ja) 2010-11-04
US7888052B2 (en) 2011-02-15
AR037223A1 (es) 2004-11-03

Similar Documents

Publication Publication Date Title
MY150237A (en) Cripto blocking antibodies and uses thereof
WO2003083041A8 (en) Cripto-specific antibodies
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
YU37304A (sh) Specifični agensi koji vezuju humani angiopoetin-2
FR12C0004I1 (OSRAM)
IL163573A0 (en) Conjugates of therapeutic or cytotoxic agents and biologically active peptides
PT1187632E (pt) Tratamento com anticorpos anti-erbb2
EP1194164B8 (en) Prion protein peptides and uses thereof
PL328858A1 (en) Immunogenous peptides
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
SI1441761T1 (sl) Postopki za preprečevanje in zdravljenje flavivirusne infekcije pri živalih
AU2001235761A1 (en) Diagnosis of breast cancer using bcmp-11 as marker
WO2002066492A3 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques.
AU2002319223A1 (en) Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein
ATE328082T1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
ATE490981T1 (de) Criptospezifische antikörper
TW200635952A (en) Specific binding agents of human angiopoietin-2
UA32280A (uk) Спосіб формування тонко-товстокишкового анастомозу бік у бік
HK1052013A (en) Liv-1 related protein, polynulceotides encoding the same and use thereof for treatment of cancer